Details
In this analysis, we described counts of new users of long-acting injectable antipsychotics (LAIAs) including paliperidone palmitate, risperidone microspheres, and haloperidol decanoate in the Sentinel Distributed Database (SDD). We estimated the two-week and four-week risk of mortality comparing (1) paliperidone palmitate users to risperidone microspheres users and (2) paliperidone palmitate users to haloperidol decanoate users. As sensitivity analyses, we also evaluated the two-week and four-week risk of mortality among subgroups by age (18-34, 35-44, 45-54, 55-64, 65-74, 75-84, and 85+ years), dementia status (dementia diagnosis and treatment, no dementia diagnosis and treatment), and LAIA administered during an institutional stay (during stay, not during stay).
This analysis is a follow-up to two previous analyses, which can be found here and here. Like the first follow-up analysis, this third analysis included continuous age in the outcome regression model in addition to using inverse probability of treatment weighting (IPTW) to adjust for confounding. Unlike the prior analyses, this analysis used average treatment effect in the treated, stabilized weights (ATTS) rather than average treatment effect in the total population, stabilized weights (ATES).
The study period includes data from January 1, 2010 to July 1, 2022. We distributed this request to one Sentinel Data Partner on March 14, 2024.
The analytic package associated with this analysis can be found externally in Sentinel's Git Repository located here. The Git Repository serves as Sentinel's version control tracking system for analytic packages and technical documentation.